Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Targeting the RAS oncogene.

Takashima A, Faller DV.

Expert Opin Ther Targets. 2013 May;17(5):507-31. doi: 10.1517/14728222.2013.764990. Epub 2013 Jan 30. Review.

2.

Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).

Sacco E, Spinelli M, Vanoni M.

Expert Opin Ther Pat. 2012 Nov;22(11):1263-87. doi: 10.1517/13543776.2012.728586. Epub 2012 Sep 26. Review.

PMID:
23009088
3.

Improving Prospects for Targeting RAS.

Singh H, Longo DL, Chabner BA.

J Clin Oncol. 2015 Nov 1;33(31):3650-9. doi: 10.1200/JCO.2015.62.1052. Epub 2015 Sep 14. Review.

PMID:
26371146
4.

The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?

Lv J, Wang J, Chang S, Liu M, Pang X.

Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):17-26. doi: 10.1093/abbs/gmv102. Epub 2015 Oct 19. Review.

PMID:
26487443
5.

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.

Asati V, Mahapatra DK, Bharti SK.

Eur J Med Chem. 2016 Feb 15;109:314-41. doi: 10.1016/j.ejmech.2016.01.012. Epub 2016 Jan 12. Review.

PMID:
26807863
6.

Past, Present, and Future of Targeting Ras for Cancer Therapies.

Tan Z, Zhang S.

Mini Rev Med Chem. 2016;16(5):345-57. Review.

PMID:
26423695
7.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM.

Oncotarget. 2012 Oct;3(10):1068-111. Review.

8.

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.

Lackner MR.

Expert Rev Mol Diagn. 2010 Jan;10(1):75-87. doi: 10.1586/erm.09.78. Review.

PMID:
20014924
9.

[Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].

Chang YS, Liu JC, Fu HQ, Yu BT, Zou SB, Wu QC, Wan L.

Yao Xue Xue Bao. 2013 May;48(5):635-41. Review. Chinese.

PMID:
23888683
10.

[Targeting the RAS signalling pathway in cancer].

Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C.

Bull Cancer. 2011 Oct;98(9):1019-28. doi: 10.1684/bdc.2011.1380. Review. French.

11.

Biomarkers downstream of RAS: a search for robust transcriptional targets.

Györffy B, Schäfer R.

Curr Cancer Drug Targets. 2010 Dec;10(8):858-68. Review.

PMID:
20718707
12.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

Guenther MK, Graab U, Fulda S.

Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.

PMID:
23684925
13.

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.

Santarpia L, Lippman SM, El-Naggar AK.

Expert Opin Ther Targets. 2012 Jan;16(1):103-19. doi: 10.1517/14728222.2011.645805. Epub 2012 Jan 12. Review.

14.

Synthetic lethal genetic screens in Ras mutant cancers.

Yu B, Luo J.

Enzymes. 2013;34 Pt. B:201-19. doi: 10.1016/B978-0-12-420146-0.00009-3. Epub 2013 Nov 7.

PMID:
25034106
15.

KSR as a therapeutic target for Ras-dependent cancers.

Neilsen BK, Frodyma DE, Lewis RE, Fisher KW.

Expert Opin Ther Targets. 2017 May;21(5):499-509. doi: 10.1080/14728222.2017.1311325. Epub 2017 Apr 7. Review.

PMID:
28333549
16.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

17.

New druggable targets in the Ras pathway?

Matallanas D, Crespo P.

Curr Opin Mol Ther. 2010 Dec;12(6):674-83. Review.

PMID:
21154159
18.

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.

Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Review.

PMID:
21494257
19.

Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.

Aguilar BJ, Zhou H, Lu Q.

Curr Med Chem. 2017;24(32):3485-3507. doi: 10.2174/0929867324666170602082956. Review.

PMID:
28571533
20.

K-Ras protein as a drug target.

McCormick F.

J Mol Med (Berl). 2016 Mar;94(3):253-8. doi: 10.1007/s00109-016-1382-7. Epub 2016 Mar 9. Review.

Supplemental Content

Support Center